Maxim analyst Anthony Vendetti downgraded Nuwellis to Hold from Buy, citing ongoing capital constraints and the “significant” shareholder dilution from the public offering of 11,250,000 shares of its common stock and warrants to purchase up to an aggregate of 16,875,000 shares of its common stock that priced a combined public offering price 24c per share and associated warrant.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NUWE:
- Nuwellis Announces Pricing of $2.7 Million Public Offering
- Nuwellis: Henry Ford offers ultrafiltration therapy to heart failure patients
- Nuwellis Announces Launch of Ultrafiltration Therapy Using Aquadex Smartflow® System at Henry Ford Health
- Nuwellis, Inc. on the Brink: Racing Against Time to Avoid Nasdaq Delisting
- Nuwellis announces results from clinical data anaylses of AVOID-HF trial
